The Role of Synovectomy in Pain Reduction Following Total Knee Arthroplasty

NCT05800457 · tracked via the Priya Life Science Canada tracker

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase

Not applicable

Started

2023-11-20

Last updated

2026-09-22

Condition(s) studied

Osteoarthritis, Knee

Investigational drug(s) / intervention(s)

Partial synovectomy

Partial synovectomy: Patients in the intervention group will undergo partial synovectomy during total knee replacement surgery

Study summary

Osteoarthritis (OA) is the most common joint disease, causing severe pain due to joint inflammation (synovitis). While total knee arthroplasty (TKA) is commonly performed to reduce pain, 20% of patients are dissatisfied with their outcome post-surgery. This dissatisfaction is caused by persistent pain post-TKA due to synovitis that is not routinely removed during surgery. To address this problem, a synovectomy can be performed during TKA, which involves resecting the inflamed layer of tissue lining the joint, called the synovium, and its associated sensory nerve endings. Since the synovium will regenerate in the months post-surgery, synovectomy only transiently reduces pain after TKA. The proposed study will help ascertain the benefits and effects of synovectomy in patients who are more likely to experience poor satisfaction (driven mostly by pain) post-TKA. This study will include 62 patients undergoing TKA due to end-stage OA who have moderate to severe synovitis, as determined by ultrasound assessment. Patients will be randomized (1:1) to undergo a TKA with synovectomy or without synovectomy. Primary and secondary outcomes will be assessed through patient-reported levels of pain and function, results from physical performance tests, and quality of life (QOL) scores. These measures will be recorded pre- and post-surgery for comparison. Through demonstrating that synovectomy can at least transiently reduce pain post-TKA, this study will provide evidence for the development of medical therapies that target the synovium to slow its regrowth. This will be transformative for the long-term management of joint pain and synovitis post-surgery, thus significantly improving patients' overall QOL.

Eligibility

Sex

ALL

Min age

41 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: 1. Males or females over the age of 40 diagnosed with knee osteoarthritis 2. Scheduled for first unilateral total knee arthroplasty 3. Moderate to severe (at least grade two) synovitis and synovial hyperplasia, as determined by ultrasound assessment 4. Referred to the Pre-Admission Clinic at University Hospital Exclusion Criteria: 1. Bilateral, uni-compartmental, or revision total knee arthroplasty 2. Osteoarthritis due to genetic syndromes (e.g., Ehlers-Danlos Syndrome, etc.) 3. Known inflammatory arthropathy, another rheumatic disease, or disease-modifying anti-rheumatic drug (DMARD) use (e.g. methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, TNF inhibitors, etc.) - note: Gout is NOT an exclusion 4. Joint injection (steroid or viscosupplement) within 12 weeks of Pre-Admission Clinic appointment date 5. Cannot read, write, or understand English (printed instructions are provided in English only) 6. Any factors precluding patients from attending follow-up appointments (e.g., socio-economic limitations, distance from clinic, no access to home/cell phone, etc.). 7. Cognitive impairment or psychological problems that preclude the ability to understand instructions 8. Not able to follow up at routine standard of care post-operative visits

Primary outcome measure(s)

Patients' self-reported level of pain — 12 weeks post-surgery
Pain will be measured using the pain sub-scale (nine items) of the Knee injury and Osteoarthritis Outcome Score (KOOS). Each question on the KOOS is a self-administered questionnaire is assigned a score from zero (no problems) to four (extreme problems) using a five-point Likert scale. The average of each sub-scale is calculated independently. Sub-scale scores range from zero (minimum), indicating severe knee problems, to 100 (maximum), indicating no knee problems (therefore, a higher score is better). The KOOS has demonstrated face validity and construct validity, as well as excellent test-retest reliability for each domain. It has also shown to be responsive to change in patients with knee OA.

Trial sites (1)

Facility	City	Region	Status
London Health Sciences Centre - University Hospital	London	Ontario	Recruiting

More London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's trials in Canada

Pramipexole and the Risk of Serious Adverse Events Active, not recruiting

Fluid Intake After Hemodialysis Recruiting

Intermittent Fasting for Inflammation and Depression in Spinal Cord Injury Starting soon

Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis Starting soon

Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia Starting soon

Other trials for the same condition

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain Recruiting

The Impact of Procedural Awareness of Knee Injections for Osteoarthritis on Patient Perceptions of Effectiveness Active, not recruiting

Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis Active, not recruiting

Genicular Radiofrequency Ablation Following Total Knee Arthroplasty Active, not recruiting

Stopping OsteoARthritis After an ACL Tear Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05800457 on ClinicalTrials.gov ↗ ← All trials in Canada